Compare · MLTX vs NVO
MLTX vs NVO
Side-by-side comparison of MoonLake Immunotherapeutics (MLTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 153.8x MLTX ($1.45B).
- Over the past year, MLTX is down 63.3% and NVO is down 22.5% - NVO leads by 40.7 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for MLTX).
- Both have 25 recent analyst ratings on file.
- Company
- MoonLake Immunotherapeutics
- Novo Nordisk A/S
- Price
- $19.69+3.66%
- $50.31-2.25%
- Market cap
- $1.45B
- $222.81B
- 1M return
- +4.29%
- +15.47%
- 1Y return
- -63.26%
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 3
- 4
- Recent ratings
- 25
- 25
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MLTX
- Chief Executive Officer Santos Da Silva Jorge sold $2,046,205 worth of Class A ordinary shares (102,225 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,774,893 units (SEC Form 4)
- Chief Executive Officer Santos Da Silva Jorge sold $956,933 worth of Class A ordinary shares (47,775 units at $20.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 2,877,118 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
- Chief Financial Officer Bodenstedt Matthias sold $862,205 worth of Class A ordinary shares (39,120 units at $22.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,115,435 units (SEC Form 4)
- MoonLake Immunotherapeutics Announces Proposed Public Offering
- SEC Form 424B5 filed by MoonLake Immunotherapeutics
- SEC Form 4 filed by Director Bvf Partners L P/Il
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S